Patients undergoing dialysis shown to maintain antibody response for at least 6 months following SARS-CoV-2 infection
COVID-19 monoclonal antibodies reduce risk of hospitalization and death
18 May 2021Portable, affordable, accurate, fast: Team invents new COVID-19 test
18 May 2021Patients undergoing dialysis shown to maintain antibody response for at least 6 months following SARS-CoV-2 infection
A large cohort study found that despite impaired immunity, the vast majority of patients receiving dialysis maintained SARS-CoV-2 antibody levels 6 months after infection. A slow and continual decline in median antibody levels was observed over time, but the researchers found no indication that subgroups with impaired immunity had a shorter-lived humoral response compared with a healthy population. The findings are published in Annals of Internal Medicine.
